Glaukos Corporation

NYSE:GKOS

Medical - Devices

Healthcare
$233.08 -0.14%

-$0.18 today

Market cap
$13.80B
Beta
0.81
P/E (TTM)
-39.0
EPS (TTM)
-$3.26
52W Low $73.16High $148.11

Volume 1.12M

Average 0.94M

GKOS EBITDA Margin

EBITDA as a percentage of revenue.

Glaukos CorporationNYSE: GKOS

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to -3.0%

EBITDA Margin was -3.0% in Q2 FY2026, up 3.9 pp from a year earlier. On a trailing-twelve-month basis it was -23.0%, down 12.0 pp year over year. Over 3 fiscal years it narrowed by 11.5 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 11 analysts of 13.3% for the fiscal year ending Dec 2026, up from -28.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-3.0%+0.5 pp QoQ
Last fiscal yearDec 2025
-28.8%-3.8 pp YoY
LTMJun 2026
-23.0%-12.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+3.9 pp+5.9 pp+2.0 pp
1 year-3.8 pp+42.1 pp+46.0 pp
3 years-11.5 pp+48.9 pp+60.5 pp
5 years+55.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-28.8%
Year-over-year change
-3.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How GKOS compares with its peers on the latest reported figures

  • GKOS's LTM Jun 2026 EBITDA Margin of -23.0% is the 4th highest of the 8 companies compared; the peer median is -33.9%.
  • Its year-over-year change of -12.0 pp is the 5th highest of 8, against a peer median of -0.9 pp.
  • Over three fiscal years its change of -11.5 pp compares with a peer median of -5.4 pp.
GKOS Competitors Peer median
EBITDA Margin for GKOS and competitors
Company Period LTM level YoY 3-year change
ALCAlcon Inc.LTM Sep 202625.4% -0.9 pp+4.0 pp
BLCOBausch + Lomb CorporationLTM Jun 202613.9% +4.5 pp-5.4 pp
STAASTAAR Surgical CompanyLTM Apr 2026-1.4% +10.6 pp-48.3 pp
GKOSGlaukos CorporationLTM Jun 2026-23.0% -12.0 pp-11.5 pp
RXSTRxSight, Inc.LTM Mar 2026-33.9% -19.3 pp+89.0 pp
SGHTSight Sciences, Inc.LTM Mar 2026-39.8% +16.3 pp+70.4 pp
OCULOcular Therapeutix, Inc.LTM Mar 2026-527.0% -231.3 pp-361.8 pp
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-3415.1% -3156.5 pp-497.7 pp
SGPSpyGlass Pharma, Inc. Common StockFY2025— ——
Peer median (excluding GKOS) -33.9%-0.9 pp-5.4 pp

Competitors are the stored peer set for GKOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue294.01M282.86M314.71M383.48M507.44M
Cost of Revenue66.63M68.98M75.58M94.03M114.23M
Gross Profit227.38M213.88M239.14M289.45M393.22M
Gross Margin77.3%75.6%76.0%75.5%77.5%
Research & Development101M123.27M138.77M136.43M150.61M
Selling, General & Admin179.26M192.93M224.07M262.85M329.34M
Operating Expenses260.26M296.2M367.84M411.82M479.95M
Depreciation & Amortization34.42M35.95M37.98M39.92M42.35M
EBITDA(1.47M)(48.76M)(82.12M)(95.64M)(146.06M)
EBITDA Margin-0.5%-17.2%-26.1%-24.9%-28.8%
Operating Income(32.87M)(82.31M)(128.7M)(122.37M)(86.73M)
Operating Margin-11.2%-29.1%-40.9%-31.9%-17.1%
Interest Income1.29M2.38M9.16M11.11M10.71M
Interest Expense13.37M13.72M13.63M10.04M4.64M
Other Income / Expenses(16.4M)(16.12M)(5.03M)(23.24M)(106.31M)
Income Before Tax(49.27M)(98.43M)(133.73M)(145.6M)(193.04M)
Pre-Tax Margin-16.8%-34.8%-42.5%-38.0%-38.0%
Income Tax Expense326K766K934K771K(5.35M)
Net Income(49.59M)(99.2M)(134.66M)(146.37M)(187.69M)
Net Margin-16.9%-35.1%-42.8%-38.2%-37.0%
EPS (Basic)(1.07)(2.09)(2.78)(2.77)(3.28)
EPS (Diluted)(1.07)(2.09)(2.78)(2.77)(3.28)
Weighted Avg Shares46.42M47.44M48.43M52.76M57.19M
Weighted Avg Shares (Diluted)46.42M47.44M48.43M52.76M57.19M

Glaukos Corporation

NYSE:GKOS

Intrinsic Alpha fair value

Locked

Current Price

$233.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.